Genentech (NYSE: DNA) is among the world's leading biotechnology companies. Our focus is on developing innovative therapies that address significant unmet medical needs and positively impact the world of human health. Genentech manufactures and commercializes multiple products for a variety of medical conditions, including cancer, rheumatoid arthritis, heart attack, allergic asthma, psoriasis, stroke, growth hormone deficiency, cystic fibrosis and neovascular wet age-related macular degeneration (AMD).

Genentech's Investor Fact Sheet is updated on a quarterly basis and is intended to provide investors with a brief summary of news and events within that period.

The fact sheet may be downloaded (PDF). Additional copies may also be requested through our literature request form.

Download PDF (2.17MB)